"Enhancing cancer cell attack by expanding central memory cells and regulating immunosuppressive cells"
[by Yu, Suin] Vaxcellbio announced on September 29 that it has secured patent registration for a technology designed to cultivate and activate bone marrow-infiltrating lymphocytes (MIL) to enhance their capacity to attack cancer cells.
The patent encompasses a method for culturing lymphocytes derived from the 에볼루션 바카라 사이트 marrow of multiple myeloma patients over a 14-21 day period, involving exposure to specific cytokines (IL-2, IL-7, IL-15) and anti-CD3/anti-CD28 antibodies. Throughout this process, the MILs demonstrated an increased proportion of CD8+ memory T cells and a reduction in immunosuppressive regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), thereby enhancing their cytotoxic activity against cancer cells. The study additionally reported elevated CD107a expression, another indicator of tumor cell-killing capacity.
에볼루션 바카라 사이트 is advancing the development of BCMA CAR-MIL, a treatment candidate for multiple myeloma that enhances cancer cell cytotoxicity by incorporating the B-cell maturation antigen (BCMA) gene into bone marrow-infiltrating lymphocytes cultured through this patented technology, utilizing chimeric antigen receptor (CAR) technology.
"Conventional CAR-T therapies are derived from lymphocytes isolated from peripheral blood, which results in low tumor specificity and vulnerability to tumor escape and antigen loss, ultimately contributing to cancer recurrence," explained Lee Je-jung, CEO of 에볼루션 바카라 사이트. "In contrast, CAR-MIL therapy is developed from lymphocytes extracted from the bone marrow. Given their high proportion of central memory cells, these lymphocytes retain recognition of diverse cancer cell targets in the bone marrow and possess the capacity to return there. This enables them to track and kill malignant cells in the bone marrow over extended periods."
To date, no therapy using bone marrow-infiltrating lymphocytes engineered to express BCMA CAR has been commercialized globally, positioning 에볼루션 바카라 사이트 at the forefront of R&D in this field. In June, the company’s BCMA CAR-MIL research and development received official recognition from a government agency and was selected as part of a national new drug development initiative.
With the patent registration, 에볼루션 바카라 사이트 now holds a total of 14 patents, including two in Japan. Notably, six of these patents have been secured this year alone, among them the present registration and a Japanese patent. These include: a composition for proliferating natural killer cells using feeder cells, a monobody-based chimeric antigen receptor, and a novel method for manufacturing natural killer cells along with an associated therapeutic application for liver cancer. Collectively, these achievements have reinforced 에볼루션 바카라 사이트's technological competitiveness in the cell therapy field and expanded its intellectual property portfolio both in Korea and internationally.